Physician profile
Ronald Tang
NPI 1609022383
$46,218.77
in general payments reported to CMS, 2019-2025
85 companies · $7,064 in 2025
The $7,064 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,569 · 2020: $9,651 · 2021: $6,026 · 2022: $4,574 · 2023: $5,344 · 2024: $11K · 2025: $7,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $4,775 · Long Term Medical Supply Or Device Loan: $1,931 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,389.09 |
| Consulting Fee | $4,775.00 |
| Long Term Medical Supply Or Device Loan | $1,931.48 |
| Education | $303.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,005.50 | 2019-2025 | Enhertu, Imfinzi, Tagrisso |
| Pfizer INC. | $4,910.60 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $3,104.80 | 2019-2025 | |
| Adc Therapeutics America, INC. | $2,520.37 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $2,131.73 | 2020-2025 | Xpovio |
| Glaxosmithkline, LLC. | $2,124.97 | 2020-2025 | Jemperli, Zejula, Blenrep |
| Gilead Sciences, INC. | $1,915.22 | 2021-2025 | Trodelvy |
| Beigene USA, INC. | $1,564.68 | 2023-2025 | Tevimbra, Brukinsa |
| Merck Sharp & Dohme LLC | $1,323.82 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $1,307.98 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $1,114.43 | 2019-2025 | Opdivo, Opdualag |
| Immunomedics, INC. | $1,000.00 | 2020 | |
| Genentech USA, INC. | $994.67 | 2019-2025 | Venclexta, Phesgo, Itovebi |
| Exelixis INC. | $977.19 | 2019-2025 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $849.04 | 2019-2025 | Iclusig, Fruzaqla, Ninlaro |
Show all 83 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $769.99 | 2019-2025 | Libtayo |
| Incyte Corporation | $745.44 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Bayer Healthcare Pharmaceuticals INC. | $730.14 | 2019-2025 | |
| Daiichi Sankyo INC. | $728.25 | 2019-2025 | Enhertu, Datroway |
| Genzyme Corporation | $725.03 | 2019-2025 | |
| Amgen INC. | $721.92 | 2019-2023 | Lumakras, Vectibix, Xgeva |
| Celgene Corporation | $621.78 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Sirtex Medical INC | $617.93 | 2019-2023 | Sir-Spheres Microspheres |
| Ipsen Biopharmaceuticals, INC | $598.36 | 2020-2025 | Somatuline Depot, Onivyde |
| Seagen INC. | $571.94 | 2019-2023 | Adcetris, Padcev |
| Eisai INC. | $505.31 | 2021-2025 | |
| Emd Serono, INC. | $425.84 | 2019-2024 | Bavencio |
| Abbvie INC. | $363.15 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.80 | 2019-2025 | Gilotrif |
| Puma Biotechnology, INC. | $308.29 | 2019-2025 | |
| Lilly USA, LLC | $304.99 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Mirati Therapeutics, INC. | $285.42 | 2023-2024 | Krazati |
| Array Biopharma INC | $274.62 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Jazz Pharmaceuticals INC. | $249.67 | 2020-2025 | |
| Pharmaessentia USA Corporation | $235.27 | 2023-2025 | Besremi |
| Astellas Pharma US INC | $233.34 | 2019-2025 | Xtandi, Padcev, Xospata |
| Kite Pharma, INC. | $200.26 | 2019-2024 | Yescarta |
| Taiho Oncology, INC. | $177.15 | 2020-2025 | |
| Rigel Pharmaceuticals, INC. | $172.17 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmacyclics LLC, An Abbvie Company | $165.20 | 2019-2022 | |
| Immunogen, INC. | $152.33 | 2023-2024 | Elahere, Elahere |
| Janssen Scientific Affairs, LLC | $144.81 | 2023 | Erleada |
| Deciphera Pharmaceuticals INC. | $133.52 | 2022-2025 | Qinlock |
| Alexion Pharmaceuticals, INC. | $129.85 | 2019-2025 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $127.17 | 2021-2025 | Fotivda |
| Sumitomo Pharma America, INC. | $124.50 | 2023-2025 | Orgovyx |
| Beone Medicines USA, INC. | $93.47 | 2025 | Brukinsa |
| Tersera Therapeutics LLC | $92.14 | 2021-2025 | Xermelo |
| Sobi, INC | $89.08 | 2023-2025 | |
| Blueprint Medicines Corporation | $87.01 | 2023 | Ayvakit |
| Clovis Oncology, INC. | $73.97 | 2019-2020 | |
| Morphosys, US INC. | $73.18 | 2021-2023 | Monjuvi |
| Mylan Institutional INC. | $63.08 | 2019 | |
| Ge Healthcare | $62.69 | 2022 | |
| Stemline Therapeutics INC. | $62.48 | 2023-2025 | Orserdu |
| Dova Pharmaceuticals | $47.15 | 2020 | |
| Alnylam Pharmaceuticals INC. | $45.94 | 2022-2023 | Givlaari |
| Myovant Sciences INC. | $45.32 | 2021-2022 | |
| Epizyme, INC. | $42.29 | 2020-2022 | |
| Foundation Medicine, INC. | $41.35 | 2019-2020 | |
| Iovance Biotherapeutics, INC. | $40.49 | 2025 | Amtagvi |
| Recordati_rare_diseases_inc. | $37.11 | 2025 | Enjaymo |
| Servier Pharmaceuticals LLC | $36.33 | 2025 | |
| Tesaro, INC. | $29.54 | 2019 | |
| Octapharma USA, INC. | $27.34 | 2025 | Panzyga |
| Springworks Therapeutics, INC. | $26.60 | 2025 | Ogsiveo |
| Azurity Pharmaceuticals, INC. | $25.93 | 2025 | Danziten |
| Tolmar Pharmaceuticals, INC. | $24.60 | 2020 | |
| Kyowa Kirin, INC. | $23.82 | 2025 | |
| Coherus Oncology, INC. | $23.42 | 2025 | Loqtorzi |
| Sanofi-Aventis U.S. LLC | $23.23 | 2019 | |
| Fennec Pharmaceuticals, INC. | $23.09 | 2025 | Fyarro |
| Myriad Genetic Laboratories, INC. | $23.05 | 2024 | Myrisk |
| Catalyst Pharmaceuticals, INC. | $22.54 | 2023 | Firdapse |
| Lexicon Pharmaceuticals, INC. | $22.12 | 2020 | |
| Global Blood Therapeutics, INC. | $21.85 | 2021 | |
| Pharmacosmos Therapeutics INC. | $20.59 | 2025 | Monoferric |
| Geron Corporation | $19.51 | 2024 | Rytelo |
| Progenics Pharmaceuticals, INC. | $17.96 | 2025 | |
| Vivus LLC | $16.96 | 2023 | Pancreaze |
| Heron Therapeutics, INC. | $16.54 | 2019 | |
| Tolmar, INC. | $16.13 | 2023 | |
| Tactile Systems Technology INC | $14.43 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.